Navigation Links
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
Date:2/13/2009

d are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with our ability to obtain future financing and fund the product development of our pipeline; our ability to estimate accurately the amount of cash to be used to fund operations; unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2008 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

                          ---FINANCIALS ATTACHED---



                             Pharmacyclics, Inc.
                       (a development stage enterprise)
                      Condensed Statements of Operations
              (unaudited) (in thousands, except per share data)

                                        Three Months Ended  Six Months Ended
                                 
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
2. Pharmacyclics Secures $5.0 Million in Debt Financing
3. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
4. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
5. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
6. Pharmacyclics Announces It Received Nasdaq Notification
7. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
8. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
9. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
10. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
11. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 21, 2011 MO BIO Laboratories, Inc., ... purification, announces the launch of the RTS DNase™ Kit, ... enzyme. (Photo: http://photos.prnewswire.com/prnh/20110921/LA65994 ) ... from RNA preparations while protecting valuable RNA samples from ...
... Silence Therapeutics plc (AIM: SLN) ("Silence", the "Group" or ... company, today announces the appointment of Tony Sedgwick PhD, ... Sedgwick will be based in Silence,s London office and ... Tony Sedgwick is an experienced biotechnology and pharmaceutical ...
... SANTA CRUZ, Calif., Sept. 20, 2011 SomaGenics, Inc., ... data on the efficacy of RNA interference (RNAi) therapeutics ... sshRNA platform. SomaGenics, along with its ... in a poster entitled "Synthetic Short shRNAs are Potent ...
Cached Biology Technology:MO BIO Laboratories, Inc. Launches the RTS DNase™ Kit 2Appointment of Chief Business Officer 2Appointment of Chief Business Officer 3SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 2SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 3
(Date:4/24/2014)... published in the Scientific Reports journal. , CSIC ... joint centre of CSIC and Pompeu Fabra University-UPF), explains: "When ... we saw that it did not match with the DNA ... the complete genome and to make a functional interpretation in ... Louis XVI". , The functional genome analysis was based ...
(Date:4/24/2014)... Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified ... system to discriminate between viral and endogenous RNAs ... they take control of cellular metabolism and hijack ... This process is dependent on viral RNA molecules ... of RNA viruses) and/or newly synthesized in the ...
(Date:4/24/2014)... State University and the University of North Carolina at ... could help identify arterial plaque that is at high ... stroke. , At issue is the plaque that builds ... plaque are deemed "vulnerable," meaning that they are more ... heart attack or stroke. , "Existing state-of-the-art technologies are ...
Breaking Biology News(10 mins):The blood preserved in the pumpkin did not belong to Louis XVI 2Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3New ultrasound device may add in detecting risk for heart attack, stroke 2
... researchers have shown natural radioactivity within DNA can alter ... The research, recently published in Biochimica et ... at natural radioactivity within human DNA on the atomic-scale. ... as well as in every living organism across the ...
... 2013 In the past decade, a single strain of ... become the main cause of bacterial infections in women and ... a study published today in the American Society for Microbiology,s ... resistant to antibiotics, the strain H30-Rx gained an unprecedented ability ...
... climate and biosphere modelling suggests that the length of time ... known as ,residence time, - is the key "uncertainty" in ... all life - will respond to higher CO2 levels and ... time in vegetation as the negative impacts of climate change ...
Cached Biology News:Radioactivity muddles the alphabet of DNA 2Epidemic of Escherichia coli infections traced to 1 strain of bacteria 2Epidemic of Escherichia coli infections traced to 1 strain of bacteria 34 degree rise will end vegetation 'carbon sink' 24 degree rise will end vegetation 'carbon sink' 3
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Phospho-Chk1 (Ser296) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
Biology Products: